Telix Pharmaceuticals shares (ASX: TLX) regained almost half of Monday’s A$2.09 pullback in Tuesday’s trading session, closing out the day up 6.54% at A$16.79, up A$1.03 per share. This followed a heavily negative start to the week that saw the Telix share price fall A$2.09. What’s more interesting is that the same reasons for Monday’s pullback were also cited as being behind the reason behind an analyst upgrade on the day.
Tuesday’s partial rebound came as RBC upgraded the stock to Outperform, triggered by the company’s landmark US$2.35 billion acquisition of ITM Isotope Technologies Munich SE, arguing the market’s reaction has created a compelling entry point into one of the ASX’s most strategically positioned radiopharmaceutical companies.
Telix shares fell 11.71% to A$15.76 on Monday, as markets digested the scale and structure of the ITM deal. The sell-off was driven primarily by concerns over equity dilution, with Telix issuing approximately 105.8 million new shares valued at around US$1.25 billion as part of the upfront consideration. The move hands ITM shareholders a roughly 23.7% stake in the combined group, leaving existing Telix shareholders with around 76.3%.
The decline was not entirely surprising, as large-scale acquisitions funded partly through stock routinely trigger near-term price pressure, particularly when the deal involves a target carrying meaningful debt. Telix is assuming approximately US$302 million in net debt as part of the transaction, bringing total upfront consideration to US$1.65 billion on a cash-free, debt-free basis. An additional US$700 million in milestone payments is contingent on regulatory approvals and commercial sales benchmarks through to 2030.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Despite the sell-off, RBC Capital analyst Craig Wong-Pan moved swiftly to upgrade Telix from Sector Perform to Outperform, lifting his 12-month price target from A$19 to A$21, implying a healthy upside from here. For more details on the ITM acquisition itself, see our post here from earlier in the week.
What Lay Ahead
RBC’s upgrade is grounded in the view that the market has mispriced the long-term strategic and financial benefits of the ITM transaction. Wong-Pan noted that the acquisition price appears reasonable when assessed against peer transaction multiples and ITM’s growth profile, and that the combined entity is now materially undervalued at current share price levels. William Blair has also described the deal in strongly positive terms, characterising the acquisition as a supercritical strategic move for Telix’s long-term competitive positioning.
The bull case rests on vertical integration reducing supply risk and improving margins, ITM’s existing profitable revenue base accelerating Telix’s path to sustained EBITDA, and ITM-11’s clinical profile offering a credible route into the GEP-NETs market should FDA manufacturing issues be resolved in a timely manner.
Whether the market’s initial caution or RBC’s upgrade proves correct will depend heavily on the pace of ITM-11’s regulatory resolution and management’s ability to integrate a complex cross-border manufacturing business while sustaining the commercial momentum of its existing portfolio. With Telix’s share price up 47.8% since the turn of 2026, yet 44% off the highs of early 2025, the stock sits neatly balanced.
